New study predicts changing Lyme disease habitat across the West Coast Posted Tuesday March 16, 2021 Army of ‘citizen scientists’ collect more than 18,000 tick samples for analysis in study funded by Bay Area Lyme Foundation
TGen seeks help from Arizona dog and cat owners for COVID-19 study Posted Wednesday March 10, 2021 Project builds on ‘One Health’ testing and disease surveillance collaborations in Arizona
Men, older adults and smokers are more prone to infection by SARS-CoV-2 Posted Wednesday March 3, 2021 Study provides answers to who and why COVID-19 poses increased risk and potential death among certain demographics
TGen-led study confirms cell-free DNA in urine as potential method for cancer detection Posted Wednesday February 17, 2021 If successful, non-invasive method could transform detection and treatment outcomes
Exact Sciences to Acquire Ashion Analytics and Enter Research Collaboration with City of Hope’s Genomics Institute, TGen Posted Tuesday February 16, 2021 Provides Access to Industry-Leading Sequencing Lab and Plans for 10-Year Partnership with National Cancer Research Leaders
15-year-old TGen patient and NASA devotee prepares for Mars landing Posted Tuesday February 16, 2021 Feb. 18 celebration hopes to raise $30,000 for TGen Center for Rare Childhood Disorders
Applications for TGen summer programs close Feb. 5 Posted Monday February 1, 2021 Helios Scholars at TGen and TGen Bioscience Leadership Academy provide hands-on experience for students
TGen-led study results suggest a more accurate diagnostic for breast cancer Posted Tuesday January 26, 2021 Proteomics-based technology could help verify mammography screening
TGen-NAU study results show COVID-19 virus triggers antibodies from previous coronavirus infections Posted Tuesday January 19, 2021 Findings suggest that prior immune experience could affect the course of patient’s disease
Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology Posted Wednesday January 13, 2021 Worldwide Exclusive License Provides Access to Targeted Digital Sequencing (TARDIS) Blood Biopsy Method for Use in Minimal Residual Disease Testing